Different Types of Childhood Cancer | INTEGRIS – Integris

If youre a parent, you know the thoughts, feelings and emotions that come with protecting your child. Youd do anything for them to ensure they live a long, healthy life. But what will you do when there are times when health conditions, such as childhood cancer, stand in the way?

Cancer in children is more common than you may think, as it accounts for the second-leading cause of death behind accidents. While a cancer diagnosis, or even the thought of your child developing cancer one day, is overwhelming, modern medicine has improved survival rates. As with any cancer, early detection is key. To help you familiarize yourself with childhood cancer, we asked Michael Confer, M.D., a radiation oncologist at the INTEGRIS Cancer Institute, about the different types of cancers, which signs to look for and how they can be treated.

Unlike adult cancers, which can result from the environment or exposure to certain things, childhood cancers result from genetic mutations that occur early on in life or before birth.

It all comes down to changes in genes. Your DNA contains information to make different types of cells in your body. In other words, your skin cells contain information to be brain cells, while your kidney cells contain information to be heart muscle cells. As cells mature, they become specialized, turning on and off certain genes to allow them to perform specific duties. Cells need to be able to replicate to replace damaged cells of the same category. They grow with help from genes called proto-oncogenes.

When your DNA changes, it leads to genetic mutations, and cells can become permanently activated. This can lead to cells duplicating uncontrollably, known as cancer.

Tumor suppressor genes slow down cell division. They repair DNA mistakes before cells divide and control cells internal death process (apoptosis or programmed cell death), Dr. Confer says. DNA mutations within tumor suppressor genes can also allow cells to duplicate uncontrollably. Children can be born with mutated proto-oncogenes or tumor suppressor genes in certain cells. These abnormally programmed cells lead to most childhood cancers.

So, what causes DNA changes? Your child can inherit genes from a parent that increases their risk of cancer or they can acquire these genes. Cancers from acquired, sporadic gene mutations are more common than those from inherited gene mutations 5% of all childhood cancers come from inherited mutations.

Breast cancer and ovarian cancer are the most common types of cancer caused by inherited DNA changes from BRCA1 or BRCA2 gene mutations. Even with how well-known these are, only 5 to 10% of breast cancer cases come from BRCA1/BRCA2 inherited mutations. Plus, breast cancer and ovarian cancer are more common in adults than children. Talk to your doctor or visit a genetic counselor if you have specific questions about inherited mutations.

Cancer can impact any part of your body, ranging from your bones and blood cells to your brain, spinal cord and other internal organs. You may be most familiar with leukemia, lymphoma, and brain and spinal tumors, since they are the most common. But, here is a full overview of cancers that commonly affect children, according to the American Cancer Society.

Leukemia: This is the most common type of cancer in children, accounting for 28% of cases. It generally starts in white blood cells and becomes fast growing (acute). Acute lymphocytic leukemia (ALL) and acute myeloid leukemia (AML) are the two most common types of leukemia. Three out of every four children with leukemia have ALL. This type of cancer starts in the lymphoid cells, called lymphocytes, whereas AML starts in myeloid cells. Chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL) are two types of rare cancers

Brain and spinal cord tumors: These types of cancers make up 26% of all cases. Brain tumors are more common than spinal cord tumors. The cancer generally starts in the lower part of the brain.

Neuroblastoma: This type of cancer affects infants and young children. Neuroblastoma starts in nerve cells during pregnancy and accounts for 6% of childhood cancers. Abdomen swelling is a common sign of neuroblastoma.

Wilms tumor: This type of cancer starts in the kidneys and impacts children who are 3 or 4 years old. It accounts for 5% of childhood cancers.

Lymphoma: Although lymphoma isnt as common as other types of cancers, youve likely heard of Hodgkin lymphoma and non-Hodgkin lymphoma, the two main types of cancer that show up in the lymphocytes. Non-Hodgkin lymphoma (accounts for 5% of childhood cancers) appears in younger children and is more common than Hodgkin lymphoma (accounts for 3%), which is more common in younger adults. You may notice a swollen lymph node under your childs arm or near their throat.

Rhabdomyosarcoma: This type of cancer develops in areas that your child uses to move their body, such as the head, pelvis, arms or legs. It accounts for 3% of childhood cancer cases.

Retinoblastoma: This cancer develops in the eyes, and your child is most at risk around the age of 2 until the age of 6. It accounts for 2% of childhood cancers.

Bone cancer: Bone cancer is more prominent in teens, but it still accounts for 3% of childhood cancers. There are two types, osteosarcoma and Ewing sarcoma, that show up via swelling around the bones. Ewing sarcoma is a less common type of cancer that is more prominent in older children and younger teens. Osteosarcoma, meanwhile, is more common in teens and in areas where bones grow quickly.

There isn't a one-size-fits-all guide to know if your child has cancer. In general, Dr. Confer says to keep an eye on any changes in your childs behavior, such as walking, eating, playing or sleeping. If theyre older, listen to any complaints they may have. Some cancers may produce a lump or swelling and pain in certain areas. Other symptoms include a loss of energy, weight loss, sudden eye or vision changes, frequent headaches with vomiting or a persistent fever that signifies the body is fighting an infection.

For example, leukemia, the most common type of childhood cancer, affects most children between the ages of 2 and 4. Typical symptoms include fever, bleeding, deep pain in the bones, small red spots on the skin called petechiae, bruises and enlarged lymph nodes.

Notify your childs pediatrician if any of these concerns arise. Aside from that, you should schedule your child for routine checkups and wellness visits.

Routine checkups and wellness visits help monitor normal growth and development. A good pediatrician-patient relationship helps the physician better identify subtle signs of cancer and gives parents a trusted sounding board for the concerns parents or children may have, Dr. Confer says.

Many childhood cancers have become increasingly treatable, leading to longer survival rates. Dr. Confer says acute lymphoblastic leukemia, lymphoma or kidney tumors known as Wilms tumor all have more than a 90% five-year survival rate (the percentage of patients who are alive five years after receiving treatment or a diagnosis).

In fact, the overall five-year survival rate for childhood cancers has improved from 58% in the mid-1970s to 84%, according to the American Cancer Society. But, certain types of aggressive cancer still exist. Diffuse intrinsic pontine glioma (DIPG), a rare brain tumor, is often cited as the childhood cancer with the poorest survival rate (less than 1% for five years).

No matter the diagnosis, continual hope and quality, proven therapies are the most important factors for children and families facing childhood cancers, Dr. Confer says.

Here are some of the most common forms of therapies to treat childhood cancer.

Surgery can help many patients, whether you need an entire tumor removed or a procedure to ease pain caused by a tumor. Your childs surgeon can also debulk a tumor, meaning they remove part of it and treat the rest with another method. Surgery has the highest success rate when its contained to one area, before the cancer has an opportunity to metastasize (spread to other parts of the body).

High doses of radiation help reduce cancer by either killing the cells or damaging their DNA to slow growth. Over time, these cells die and your body removes them. You can either receive internal or external radiation. External radiation comes from a beam that treats a specific body part, whereas internal radiation is in solid or liquid form. More specifically, brachytherapy is the medical term for solid internal radiation. Your doctor will place capsules, seeds or ribbons near the tumor. Systemic therapy is the medical term for liquid internal radiation. With this method, the radiation travels through your blood via a pill, injection or IV to kill cancer cells.

Chemotherapy comes in many methods of application, such as IV, oral, injection, topical or through a catheter, port or pump. Chemotherapy also kills healthy cells, which is one of the downsides. This is why many chemotherapy patients lose their hair and experience other side effects. Depending on the type and progression of the cancer, chemotherapy can help shrink a tumor to increase the success rate of surgery or radiation. Chemotherapy can also fight against any lingering cancer cells following surgery or radiation. Its also used to treat cancer that returns or metastasizes.

The immune system is your bodys way of defending itself against harmful germs, bacteria and viruses. When it comes to cancer, the immune system can have trouble recognizing and fighting off harmful cells because cancer starts in healthy cells. Immunotherapy helps your body pinpoint cancer kills to better defend against them. There are many types of immunotherapy treatments to boost your immune system. One type, chimeric antigen receptor (CAR) T-cell therapy, mixes your own T-cells with a virus that teaches the T-cells how to kill cancer cells.

Targeted therapy is a form of chemotherapy. But, as the name suggests, these drugs zero in on a specific area of the cancer cells. Depending on the drug, targeted therapy can change the protein levels in cancer cells or block chemical signals that help cancer cells grow. Other targeted therapy drugs can limit blood vessel production to cut off the cancer cells or distribute toxins to specifically kill the cancer while sparing healthy cells.

Stem cells, which originate in the bone marrow, make red blood cells, white blood cells and platelets. Leukemia and lymphoma start in the blood cells, causing damage to the cells your body needs to function. A stem cell transplant involves destroying cancer cells via chemotherapy and/or radiation before replacing them with new, healthy cells. This allows doctors to use stronger doses of chemotherapy or radiation knowing new cells, via a transplant, will replace old, damaged cells. Stem cell transplants can come from your own cells or the cells of another person. Donated cells are often more effective since they can help kill off cancer cells.

While you cant do anything to prevent your child from developing cancer, you can be proactive by scheduling regular checkups and looking out for warning signs and symptoms. Contact an INTEGRIS pediatrician if you have any concerns, and they can refer you to an oncologist at the INTEGRIS Cancer Institute.

Subscribe for regular emails full of useful and interesting Oklahoma-centric health and wellness info, from the doctors and health experts at INTEGRIS.

Excerpt from:
Different Types of Childhood Cancer | INTEGRIS - Integris

A perfect match: Bone marrow transplant saves twin brother’s life. Now their family pays it forward – 11Alive.com WXIA

When 5-year-old Sawyer was diagnosed with sickle cell at a young age, his fraternal twin, Saxton, turned out to be a perfect match.

ATLANTA This is not just a birthday party, its a celebration of second chances.

We are so blessed, said OShea Guillory. We want to share this.

It is also a commitment to help others, too.

Mikari Tarpley is 16. She is at the small birthday celebration and sang her heart out for 5-year-old Sawyer and his brother Saxton. She sings from a place of understanding.

She and Sawyer, her neighbor, have both been through a lot this year.

We found out about Sawyers sickle cell disease at a very early age, Guillory said. He was about three weeks old.

Sawyers mom said she was absolutely devastated. She refused to accept there was nothing she could do to help her son.

I did a ton of research," she said. I found an organization called Be The Match.

She discovered information about transplants that could be a potential cure. Doctors take stem cells from the bone marrow of a donor and transplant it into the recipient.

They just needed a donor.

It turns out Sawyer was born with his cure, Guillory said. His twin, Saxton, was a perfect sibling match.

Across the cul-de-sac, Mikari Tarpley, an actress, was fighting Hodgkins Lymphoma and finishing chemotherapy.

She knew Sawyer has been battling sickle cell. Theyd both lost their hair from treatment. She decided she wanted to use her Sweet 16th birthday to raise money for children like Sawyer.

We couldnt do much for my sixteenth because of COVID, so we thought it would be a great idea to do a fundraiser to help others, Mikari said.

She reached her goal of $16,000 to help children being treated for sickle cell disease at the Aflac Cancer and Blood Disorders Center.

Five-year-old Sawyer received a bone marrow transplant from his fraternal twin, Saxton. It was a success. Before long, Sawyer was riding a tricycle around Childrens Healthcare of Atlanta, racing his nurses and giggling along the way.

I truly have little warriors, Guillory said. My son, who helped save his brothers life - and my son - who was able to go through all of that and come out even stronger.

Now Sawyer, Saxton and their parents are spending their 5th birthday following Mikaris lead by paying it forward.

Sawyers mom OShea is starting a nonprofit, Sawyers Sickle Circle, to spread awareness and knowledge about sickle cell, Beads of Courage and Be the Match program. They launched a fundraiser on Sawyer and Saxtons birthday.

The Guillory family said the best present they could wish for is for other kids to have the chance to celebrate many more birthdays to come.

Read more here:
A perfect match: Bone marrow transplant saves twin brother's life. Now their family pays it forward - 11Alive.com WXIA

Baby whose nosebleeds turned out to be deadly condition saved by stranger – Mirror Online

A baby whose nose bleed turned out to be a one-in-a-million disease has had his life saved by a complete stranger.

Tiny Daniel McAvoy's parents were told he would die unless he received the stem cell transplant before he turned two.

The infant was diagnosed with Wiskott-Aldrich syndrome, a rare blood disorder, when he was just ten weeks old.

Mum Georgie, 30, and dad Andrew, 37, noticed something wasnt right with their newborn when he suffered chronic nosebleeds and passed blood in his nappies.

But after desperately searching for the right donor for more than a year, Daniel has now had the transplant and is a smiley, happy tot back at home.

"Hes eating and playing and I really hope it continues that way. Im just so proud of him, hes done amazing," Georgie, of Benwick, Cambridgeshire, said today.

"There were plenty of times we thought he would die - we even had him christened in hospital because things werent looking great.

"He has the most severe level of the syndrome so from day one we were told he would need a transplant to replace his faulty immune system and defective cells and the procedure took place.

Doctors warned that he would go down quickly after the transplant but he hasnt and they're shocked."

When Daniel was first referred to hospital at three weeks old, medics first thought he had leukaemia, but after recovering from sepsis, he was discharged while they continued to look into the worrying case.

He was then rushed back to hospital at ten weeks old in July last year.

Georgie, who is a stay-at-home-mum, said: The nosebleeds went from nothing to doctors then telling us that he needed a bone marrow transplant to save his life.

He was diagnosed with Wiskott-Aldrich Syndrome in July 2019, which affects only one in a million boys and was the cause of the horrendous bleeds.

I never knew I was a carrier of the gene that causes it, so as a mum I felt pretty guilty that Id given him it."

The newborn woke up in May 2019 with a crust of blood on his nostril, which his parents thought was strange but a health visitor suggested it could be from a scratch.

But the tot began passing blood in vomit and nappies, and a GP then referred him to the hospital, where tests found he had a low platelet count that caused the bleeding.

Following a platelet transfusion to help stabilise him, Daniels parents were told he contracted sepsis but could also have meningitis and a rare type of leukaemia - so he was sent to a cancer ward.

Various procedures ruled out leukemia and out of nowhere the tiny tot began to get well again, so doctors discharged him.

Georgie added: Something still didnt sit right with me but some time later he had an unrelated hernia which needed an operation, and began having nose bleeds again.

I suggested that a doctor needed to look at the bigger picture because I knew there was something wrong with my baby.

The paediatrician looked back at all of Daniels notes and thought it was Wiskott-Aldrich Syndrome, which Id never heard of before, then after the operation to remove the hernia the haematologist agreed.

Within 24 hours of him being tested for this he was pretty much diagnosed and then doctors were speaking to us about bone marrow transplants - it all went very quickly.

In Daniels case, hes had a lot of bleeding problems - he bleeds from his gut, nose, eyes and mouth - so doctors were concerned about a catastrophic bleed that would kill him.

Wiskott-Aldrich Syndrome is a primary immunodeficiency which caused Daniels bleeding and left him prone to infections such as sepsis and also cancer.

He began having antibody infusions once a week as charities such as DKMS ran their global register to find a life-saving stem cell donor for Daniel, and a match was found in September 2019.

Georgie said: We had a terrifying 12 week wait but we were really fortunate that it was quick before a match was found.

His transplant then got delayed three times - the first and second times were because he wasnt well enough, and the third time was due to coronavirus.

I just went into panic mode because I thought he was going to die from this.

But Daniels transplant finally took place after a week-long chemo and immunotherapy course.

Were taking it day by day - if its successful, within two years he should be a healthy little boy.

Its all been a mixture of feelings - its really nice how hes so young that he wont remember how awful this all is but at the same time, sitting there watching your child have chemotherapy is the most heartbreaking thing in the world.

I would do anything to switch places with him.

Now that baby Daniel has been given another shot at life, his family are now calling out for others to join the transplant registers, as four out of ten patients arent lucky enough to get a match.

Georgie added: Its incredible how an anonymous donor saved Daniels life - without that person there would be no Daniel, they are all we needed to give him a second chance at life.

Its so simple and easy to sign up, and by doing so, you could save a babys life.

If you are aged between 17 and 55 and in general good health take the first step to register as a blood stem cell donor by registering for your home swab kit at http://www.dkms.org.uk.

More:
Baby whose nosebleeds turned out to be deadly condition saved by stranger - Mirror Online

Over 40 lakh people in Telangana have developed COVID-19 antibodies: Health Minister Eatala – The New Indian Express

By Express News Service

HYDERABAD:Health Minister Eatala Rajender on Friday said that around 40 lakh people in the State are estimated to have developed Covid-19 antibodies, according to information recently revealed by the Indian Council for Medical Research (ICMR) while announcing the results of its second round of sero survey conducted across the country.

That means that around 40 lakh people about 11 per cent of the States population have been affected by Covid-19 and cured of the disease, Eatala said while inaugurating the Stem Cell and Regenerative Medicine facility at NIMS Hospital in Hyderabad, which he said will prove to be a boon for poor cancer patients.

The facility will also help in bone marrow transplantation, he added. The Health Minister, who often criticises the ICMR for its handling of the Covid-19 crisis, on Friday blasted it for frequently changing its treatment guidelines.Telangana stuck to the claims it made during the start of pandemic on the approach taken to tackle the Covid-19 crisis, which he said have now been proved right.

Outpatient capacity to be increased at NIMS: Health Min

Earlier, Telangana said that convalescent plasma therapy is not very useful, costly medications such as Tocilizumab will not work and Remdesivirs usefulness will be limited. We had also said that treatments such as steroids will be good enough to treat Covid-19 patients. All these claims, backed by Gandhi Hospital doctors, have now come true, he said.

We had said that expenditure of `10,000 and quarantine is enough to provide Covid-19 treatment to patients with mild symptoms or those who are asymptomatic. ICU and oxygen beds will be required only for patients with severe symptoms, those with comorbidities or those who are poor and living in congested space. Even these claims have come true, he added.

Stressing that Covid-19 proves fatal in only limited cases, he said that now people would have to learn to live with Covid just the way they have learnt to live with seasonal ailments. Meanwhile, Eatala said that the outpatient consultation capacity at NIMS would be increased from 2,500 to 5,000 as the hospital was being provided `250 crore in the form of loan for construction of a new outpatient block along with a few critical care units. He also said that plans are being made on having separate entry and exit points at Gandhi Hospital for the treatment of non-Covid patients as hundreds of beds are lying unutilised. The Minister also said that the State government had planned to have four hospitals similar to NIMS, of which TIMS, Gachibowli, and AIIMS, Bibinagar, have materialised. A similar hospital is also being planned in Medchal-Shamirpet region, he added.

More here:
Over 40 lakh people in Telangana have developed COVID-19 antibodies: Health Minister Eatala - The New Indian Express

How to Vote This November: A Progressive’s Opinion Redheaded Blackbelt – Redheaded Blackbelt

Every election Attorney Eric Kirk puts out a list of ballot recommendations. Here are his recommendations for our upcoming election.

Im getting these recommendations out a little early this time because you will be receiving your ballots in little over a week and I know that many of you will want to get your ballot in early to make sure it is counted, and so that it will be part of the election night count. Normally I like to wait until more of the other media and organizational endorsements come out so I can take their thoughts into account. And even when I do, once I send this thing out, I know that I will run into an article or someone will express thoughts to me which would change my analysis. Im pretty certain I will not change my intended vote on the Propositions though. If I do, I will follow up, but thats very unlikely at this point.

Thank you for your interest in my thoughts. Please contact me if you have any questions.

Proposition 14 Bond Funding of Stem Cell Research Yes

In 2004, in response to then President Bushs imposition of irrational restrictions of funding for research involving fetal stem cells, we passed Proposition 71 in response to limitations imposed on federally funded stem cell research. It established the California Institute for Regenerative Medicine which has funded over a thousand projects with about 70 institutions public and private leading to over 2500 peer-reviewed studies and thousands of clinical human trials. How productive has it been in bringing us closer to the promised miracle cures? I have read some criticisms which suggest that the successes have been overhyped and the advocates become very vague as to when, if ever, such treatments will become approved by all the appropriate agencies and start saving and improving lives by curing or mitigating such horrific diseases as Alzheimers, Parkinsons, spinal injuries, etc. Is it a boondoggle preying on false hope? I think thats a bit melodramatic. I wouldnt oppose more oversight even if it is purely informational. Im not a fan of the requirement of a 70 percent legislative supermajority to make changes in the law (though it is rare that a ballot proposition offers any such opportunity).

Proposition 14 would authorize the state to sell 5.5 billion in bonds and the payoff will be about 7.8 billion with interest. The funding is limited to about half-billion per year so it will stretch it out and maybe it will pay for itself again in all the above ways.

It will also specify that 1.5 billion to fund research and therapy for Alzheimers, Parkinsons, stroke, epilepsy, and other brain and central nervous system diseases and conditions.

Yes, there have been a number of ethics-challenged quacks pushing stem-cell snake oil, but thats not the Institutes fault. And the proposal doesnt prevent the state from cracking down on fraud, or educating the public as to the state of the science.

Opponents point to Obamas removal of Bushs research restrictions for federal funding and note that federal funding has resulted in about three times as many clinical studies as the California money. So far Trump has not restored the Bush restrictions, but it was reported in July that the President is stacking the federal ethics panel with anti-abortionists, and a vaccine in its third phase of clinical testing may be jeopardized not because its production involves fetal stem-cells, but because some of its research and development did and they oppose anything which is even merely the fruit of what they consider to be unethical research. Should Trump win a second term, that federal funding will probably be stopped.

The Prop 71 money is drying up although it generated 3 billion in matching funds (when Obama was in office) and created tens of thousands of jobs with benefits in terms of revenue and commerce (nearly 11 billion in stimulated economic activity). Im all for funding science, and if there are regulations or policies which can ensure the most productive results, then lets hear those proposals. Science is often and agonizingly slow process, but it is worth supporting regardless of how quickly utilitarian benefits arrive. We can do much worse with the money.

Proposition 15 Prop 13 Reform Yes!

This is probably one of the most important ballot measures we have had in a long time which represents a potential earthshaking break from the long impact of the tax revolt of 1978. We needed the reform as property values were taking huge leaps in certain parts of the state and counties wasted no time reassessing properties to increase their tax base. Working class people were in danger of losing their homes because they simply couldnt afford the increases in property taxes. It passed by a huge margin. Many progressives, including my parents, voted for it.

But it was an extreme measure which cost the state and local governments huge amounts of revenue and we watched our education system drop from the top five states in the country to the bottom ten within a decade as class sizes increased and education began to narrow towards an obsession with college prep at the expense of just about everything else even before the era of teaching to the test. I was in the eighth grade when it passed, and three of my favorite teachers were laid off. A really good science teacher went into hot tub sales. Fewer electives were available. And first responder systems as well as other infrastructure suffered, leading to a long string of bond issue initiatives to build one of the most ridiculously large prison systems in the world.

But you couldnt touch it. Even the mildest of reforms would be slapped down by the tax posse who had an iron grip on voters for this reason.

Among other things, Proposition 13 limited the assessment of real property to its purchase price rather than current market value. This means that if you dont sell your property or remodel it in certain ways which increase its value, you will not be reassessed and the taxes cannot be imposed at more than 1 percent of that value. Proposition 15 would exempt most commercial and industrial properties so that they will be assessed at current market value. The 1 percent rule would remain in effect. The measure would have no effect on agricultural land. And the increased revenues (estimates of 7 to 12 billion per year) would not be placed into the general fund, but into a special fund earmarked for local governments, special districts, and education (K-12 and community college).

I object to the latter part. We already have too many strings to all sorts of revenues so that the legislators are pretty much deprived of discretion when needs change from year to year. I have complained about this in the past. If we do not trust our legislators to exercise sound judgment as to spending then they shouldnt be in office.

On the other hand, it was local government and education which took the hardest hits under Proposition 13 to there is a certain logic to the earmarking.

There is some mitigation provided to protect small businesses who rent in the larger qualifying properties. The reassessments for properties of more than 50 percent of the space rented by small business will be deferred for five years. It also eliminates personal property taxes for small business and exempts up to $500,000 for larger businesses. Apparently, the hope is that this will offset increased rents.

If Proposition 13 had been introduced a decade later, there would have been competing measures less extreme as has taken place with other issues. Something like this measure might have been proposed to introduce a progressive tax element to the equation. It might have surpassed Howard Jarviss draconian measure. Homeowners needed a break. Maybe large commercial property owners didnt. And it may be that some large commercial property owners who arent dirt rich are going to have to make some tough choices. It may be that the measure discourages investment into a property which will significantly improve its value.

But it mitigates a serious revenue problem we have had for decades which has made our infrastructure and education system marginal.

There will be an intense opposition as the anti-tax folk will see any opening as a potential to lose it all. They want no precedent. Proposition 13 is practically a holy relic. But hopefully the worst aspects of it will become just that a relic.

Proposition 16 Restore Affirmative Action Yes with reservation

In 1996 voters passed Proposition 209 which effectively ended all affirmative action race considerations with regard to public university entrance and public contracts. The result was a huge drop in the presence of African Americans and Latinos on college campuses. Moreover, businesses owned by people of color and women lost contractual opportunities which some estimate to amount to a billion dollars per year.

You can say that such results are just because the missing students and business opportunities are based upon merit, but there have extensive discussions as to whether qualifications are more arbitrary than representative of intrinsic merit, and that the qualifications tend to be rigged towards a particular result. And maybe public university entrance should be based less on merit and more on individual and public benefit of the policy. These discussions are decades old and Im not going to rehash them here.

But the results of Prop 209 are clear, whether or not they are just. As of 2018, African Americans made up approximately 6% of the state population, but only 4% of undergraduate students in the UC system. Latinx students were 24.4% of UC students, but 39% of the state population. Of the UC students, 21% were white compared to 37% in California, and Asians were 33% of the UC undergraduate population compared to 15% in the state.

And this brings to the forefront a subject which has been the material for lawsuits Asians benefit the most from the lack of affirmative action and would be the most negatively impacted group by its return. Those of us who were raised in and around San Francisco are well aware of the controversies around the elite high school Lowell where Asians have been required under the quota rules to score higher on tests than other groups, including whites. For whatever reasons (which have been the subject of many research studies and analysis) Asian students tend to fare well with the entrance criteria. But if you arbitrarily exclude them, somehow, you risk very meritorious lawsuits from rejected white students who will argue that they are being hit from both sides of the equation.

I do support the goals of affirmative action and I hope that new policies can be developed which are effective and yet address the complexities.

I will close with an anecdote which almost turned me against affirmative action. I was a substitute teacher in San Francisco while I was in law school and I came to a very difficult placement. Some money had been allocated to hire a new English teacher to draw some students out of three very overcrowded English classes. In what I consider to have been a very bad administrative judgment each of three teachers was asked to name the students who should leave their classes and join the new classes. Naturally, at least two of the teachers sent all of their most challenging students. What they ended up with was four classes which were nearly unteachable. The teacher who had been hired quit within the first couple of weeks so the administration put out word for other English teachers to apply. The catch, under the policy the teacher had to be of color. I was told that there were a grand total of five or six non-white English teachers who were offered the job, but word got out from the substitute teachers and none of them wanted the job. There were white English instructors desperate enough for the job, but they couldnt be hired.

By the time I was assigned to the classes they were on their third sub and fourth teacher. Because I did not have an English certificate, I could only teach the class for 15 consecutive days then I could not be there for another few weeks. I was called back several times throughout the year and the classes were basically lost. Finally, they either broke or found a waiver to the rule and they hired a white teacher, who unfortunately had health problems and so was out of the classroom often. Whenever she was out, she had me called I took that as a great honor. And in fact, when I declined the placement one morning because I had law school exams to study for, I received a personal call from her literally begging me in tears to come in because if its anyone else I really cant come back. The last sub had the classroom telephone stolen it was later found above one of the removable tiles in the ceiling. Naturally I went in, but it was apparent to me that had there been continuity from the beginning of the year there maybe the year wouldnt have been lost for those kids. I dont know whether it was the policy itself or an administrative misconstruction which was responsible, but it failed those kids.

Assuming Proposition 16 passes I hope that the policy makers and administrators learn from the lessons which led to Proposition 209 and draw up some sound policies which benefit even white disadvantaged, because if it generates another backlash, we certainly wont get a third chance.

Proposition 17 Allow parolees to vote Yes

California does not have a felony exclusion rule for voting. And right now, anyone convicted can vote if they are on probation. However, someone on parole is still barred.

This is an easy one for me. I dont believe that the right to vote should be deprived for any reason other than a conviction for voter fraud. Prisoners should be allowed to vote.

Look. There is a slew of factors which are usually involved in the commission of a felony, depending on the nature of the crime. They include lack of empathy, lack of respect for rules, economic desperation, lack of self-restraint, momentary to long term lack of judgment, economic or other type of desperation, anger, sense of entitlement, self-centeredness, and many others sometimes in a complex combination to upset balances in the mess of human nature.

But one thing most felons have in common regardless of the motivation or impulse they experience life in alienation with society as a whole. In my experience very few who are prone to felonies bother to vote. Why? Because they dont see past themselves. Maybe they see as far as their immediate family, friends, and associates. Maybe.

A vote is a social act. An expression of connection to something larger than ones self. Larger than what one can see in their immediate social vicinity. To bother to vote you have to see what is not in your view. You have to feel connected. It makes no sense to deprive a felon of the right to vote. They probably dont even care.

If we are trying to rehabilitate, we want people to feel a stake in the society against which they have transgressed and be encouraged to engage with it. In fact, I might even support a measure which makes in-prison voting mandatory. What is the point of a punishment which reinforces the disconnect?

What is the down side to allowing them to vote? Do we have so many felons in prison and/or on parole that we are concerned about them coming together as a bloc to somehow vote in laws of criminality? Are we living in pre-Batman Gotham City? Seriously, I really dont see a downside. Even if they vote Republican, which is a possibility.

A law-and-order leftist friend of mine once told me that he viewed the act of crime as the ultimate right-wing act which in effect says, I want what I want and f anyone who gets in my way. I dont think its that simple, I see no logic in the deprivation of the vote. Its like punishing a child who snuck too many cookies by depriving them of the right to eat broccoli. Im not saying that voting is a cure for criminality. Im just saying that there is no logic to the deprivation.

So, the question of expanding the vote to parolees is a no-brainer. Yes. Of course.

Proposition 18 Expansion of Vote to Some 17-year-olds in Primaries Yes

Proposition 18 would allow a 17-year-old to vote in a primary if they will be 18 and eligible to vote in the general election which follows that primary. This is actually already in place in 18 other states and it makes sense. If you are going to vote in the general then you have a stake in who will be on the ballot in the general. And if they are engaged in the primary process, they are more likely to be informed come November. Makes sense to me. Youth engagement in politics is a perpetual challenge and in my opinion, though we do need to draw some lines, if theyre old enough to want to vote theyre probably mature enough.

Proposition 19 Senior Tax Break for Real Estate Speculation No

This proposal is not what it seems. Its actually kind of a jumbled mess. And it would be fiscally detrimental as well as potentially economically if it induces more real estate speculation.

Right now, some counties have a program which allows seniors over 55 (That makes me a senior. Weird.) to upgrade to a new home while holding on to the property tax amount of their prior home when purchasing another home within the same county or another participating county with reciprocation.

But why? Most people, of modest means, actually downsize when they get older and no longer have children and prefer to use the net equity to finance retirement or pass wealth on to heirs. If you are inclined to and can afford to buy a more expensive home, why shouldnt you pay the appropriate taxes for it? Because youre older? Proposition 13 was intended as a stop-gap measure to ensure that working class families would not lose their homes due to increasing tax burdens. Most voters who passed it did not envision it as a golden goose egg for which you could reap financial benefit in old age.

A very similar proposal was made a couple of years ago and I opposed it, as did about 60 percent of the voters. Ill just cut and paste what I wrote at the time.

It makes sense to make it easier to move, but this was written by Realtors with profit motive and isnt thought through in terms of fiscal impact or whether we really want to increase speculation and moving into larger homes at retirement. And it contains no caps on applicable home values. Elderly shouldnt be trapped in a home which may be far away from family, adequate medical care, etc., but the answer is to press for policies generating affordable housing for everyone. This is basically regressive and its kind of a new Prop 13 focusing most of its benefit towards rich baby-boomers.

Like the failed 2018 proposal, Proposition 19 once again puts no cap on increased home values, inviting speculation.

But the current measure even throws more weirdness into the mix.

It sets up a fund for the state to reimburse the counties for the loss of revenue of higher valued homes. Where does this money come from? Well, the proposal contains references to children of celebrities and evil east coast investors (I guess we dont have unethical investors here on the west coast). Basically it repeals aspects of Proposition 13 and 58 by cracking down on what is considered to be abuse of transfers from parents to adult children in which the children maintain the same assessed-value tax rates of the parents but rent the property out or hold onto it as a vacation home by requiring that the children live in the home to benefit from the tax rate (so I guess if you have multiple children all of them and their families or significant others should move into the house). Proposition 19 would limit the tax break to children who actually live in the home by requiring reassessment at market value rather than the parents purchase value. And even if you move into the home, youre limited in the tax break to the first million dollars. I mean, as Ive said I support serious reform proposals regarding Proposition 13 and even 58. But this is convoluted and will throw estate-planning for a few unnecessary loops.

Oh, and by the way it adds wildfires to the list of natural disasters for which a victim suffering a home loss could receive a tax break. And speaking of fires, 75 percent of the money will come out of the general fund to benefit firefighting this was thrown in at the last minute. 15 percent will go to reimburse counties for the loss of revenue for the senior tax break. I guess the other 10 percent stays in the general fund. Again, Im against the earmarking which deprives the legislature of its responsibility to allocate resources according to the particular needs of the particular year. But more than that, in an age of intense fire seasons, this is manipulation.

This proposition should have been disallowed in its form as it seems to violate the single-issue rule. On top of it, the measure would amount to a very convoluted Constitutional amendment and the California Constitution is already a mess because it is too easy to pass amendments.

Just, no.

Proposition 20 Very Convoluted and Complicated and One-sided Crime Bill Reform No

Over the past decade California voters have passed reforms intended to lower the prison population by reducing the number and length of prison sentences for other-than-violent crimes. In 2011 The US Supreme Court ordered California to release some of its prisoners who were suffering severe overcrowded conditions. The legislature responded by forcing counties to hold some of the state prisoners, which added strain to local systems and taxed their resources. In 2014 we passed Proposition 47 which reduced some low-level thefts and drug crimes from felonies to misdemeanors. Then we passed Proposition 57 which created sentencing and early release incentives to participate in rehabilitation programs for nonviolent crimes. Police unions were kicking and screaming the whole time arguing that it was going to result in massive chaotic dystopia across the state, during a several decades long phase in history in which crime rates have actually been declining. However, it appears that for certain types of theft in particular, such as car theft, there have actually been increases in some years, although the impact of Proposition 47 on that is a matter of strong dispute. UC Irvine conducted a study which suggests that there is no connection while the Public Policy Institute conducted a study which suggests that there is although again, the overall crime rate in California has been on a steady decline since 1990. The drafters disagree and have cited studies which suggest increased violent crime rates in some cities. And even the Public Policy Institute has concluded that there is no relationship between Proposition 47 and the spurts of violent crimes which seem to have gone up and down over the past decade mostly down.

Proposition 20 is heavily backed by police and prison guard unions.

The proposal is extremely convoluted and actually has some good ideas mixed with the bad. The weakness of Proposition 57 is that it really failed to define violent crime and the Courts have pretty much run with the statutory divisions which do not include domestic violence and sex crimes which dont involve physical force. Proposition 20 adds to the list of violent crimes over 50 crimes which ought to be on it to disqualify those convicted of the parole provisions made available by the ballot reforms. If this was all the measure did, I would have no objection. Im not against making serial theft a wobbler (can be charged as a misdemeanor or felony) in some cases, but I really do not think its necessary to make a felony out of theft of something at $250.00 in value, at least not for the first offence. The measure would make such a theft a wobbler if more than one person committed an organized retail crime.

And then the measure gets into a very detailed and extensive set of standards and practices for parole consideration, which may not be bad in and of themselves, but come strictly from a law enforcement perspective. It is the type of law which should be vetted in a legislative process, with experts and stakeholders from numerous facets of society to have input in the appropriate committees which would generate a legislative history which can provide guidance on the interpretation of the finalized law. This is not something which belongs on a ballot measure. I could list the provisions but your eyes would glaze over them. Few voters will read the proposal in its entirety, nor understand why some of the provisions are even in there.

The measure also seeks to expand DNA collection for database anyone convicted of everyone convicted of even minor theft and drug convictions on the theory that those convicted are going to move on to more serious crimes and so we should have their DNA in our system catch them. There is no accounting in the proposal for the civil libertarian notion that it is creepy for the government to be maintaining your DNA over a stupid mistake you might make in your youth. Yes, obviously you have nothing to worry about if you dont break the law again, but thats just not the point, nor is it the case

Basically, the measure would reduce the opportunities for parole and probation thats the whole point. It would result in an increase in incarceration and potentially jeopardize the states compliance with the Supreme Court order (although who knows if the order will survive the new SCOTUS makeup?). There is an extensive prison industry in California and it needs feeding, and that is whats fueling this measure. Wrong direction.

Proposition 21 Local Say in Rent Control Redux Yes

This is a watered-down version of 2018s Proposition 10 which I think lost because many people thought it was imposing a statewide rent control. It wasnt. But let me just repeat what I said two years ago.

Ive just about had it with biased documents/wording coming out of government, but the official Election Guide describes the proposition as expands local governments enact rent control Technically speaking this is true, but anyone who doesnt know the history or read the analysis carefully will fail to understand that was this does is to dial back overreach from Sacramento in the horrific Costa-Hawkins law passed by developer and Realtor lobby-pressured pols to impose statewide restrictions on rent control. Costa-Hawkins prohibits rent control for single-family homes. It prohibits vacancy rent control. And most egregiously it prohibits rent control of anything built from 1995 on which was purely a gift to developers.

This is exactly the kind of legislation conservatives claim to hate that which saps local control. It puts a premium on tearing down older homes. For the lack of vacancy rent control it assures gentrification and the destruction of working-class communities.

So, it went down in flames. Basically, the Costa-Hawkins act prohibits rent control on single-family housing, condos, townhouses and anything first occupied after 1995 (so basically nothing built within the past quarter-century and growing. Proposition 21 would basically allow property to be occupied for 15 years before it could be rent-controlled. And it would allow local governments to impose vacancy rent control. Allows rent increases on rent-controlled properties of up to 15 percent over three years from previous tenants rent above any increase allowed by local ordinance. It exempts rent control for anyone who owns no more than two home rentals.

I supported Proposition 10. Obviously, I support the more limited version as better than nothing.

Proposition 22 Exempts Uber from Labor Regulations No

The rise of the gig economy has accompanied the decline of union jobs in which a workers hours are regulated, unemployment and workers compensation insurance must be provided, and benefits pretty much non-existent as collective bargaining is not only impossible but completely contrary to the model.

Earlier in the year a California court ruled that gig workers must be treated as employees rather than independent contractors. The court granted a stay in the ruling pending appeal. Gig economy businesses have threatened to shut down their businesses saying that they cant afford to pay their contractors as employees. That threat just reveals the math.

Proposition 22 would exempt ride sharing and food delivery services from employment laws. Uber and Lyft have built their business models around the independent contractor status, reserving full-time employee status for corporate roles to keep costs low. Uber, Lyft, Doordash, Postmates, and Instacart have poured six figures of millions of dollars into the measure (some of that money no doubt the product of savings from exemption from having to pay a decent wage).

Im not a fan of the Uber model anyway. The data is in and they tend to focus their activity in public transit friendly areas which means lots more driving and traffic.

The business model is favored by many young drivers who like the flexibility, and there is mixed evidence as to whether Uber drivers make more money than taxi drivers due to optimized location and timing made inevitable by the app system. But if youre raising a family and you need to bring home a certain amount of money the flexibility is largely an illusion and your flexibility is limited by family and other needs. Sure, you can do something else, but the more the business model is allowed to flourish the bigger the negative impact on the non-hip portions of the working class who really do have to earn a living and bring home some healthcare and benefits. So, Uber closes up in California. Then maybe taxi companies who are subject to unions and overtime regulations will make comeback, perhaps even reproducing some of the app approaches which have made Uber the consumer choice. Of course, those rides arent as inexpensive, so maybe we will have to renew our quest for affordable and effective public transportation. Im sorry if the hipsters will be inconvenienced and have to go back to using public transit.

And by the way, there is nothing in the labor laws which deprives the companies of giving their workers time flexibility.

No, for a more worker-friendly economy.

Proposition 23 Dialysis Clinic Regulations Yes

Two years ago, Proposition 8 was introduced to place some regulations and profit caps on dialysis clinics of which private for-profit companies have a death grip and are being accused of having different tiers of levels of care depending on the source of your coverage specifically suggesting that Medi-Cal and Medicaid patients dont get the same quality of treatment.

Proposition 23 would require that a physician be present for all treatment except in circumstances of shortage of availability. It would require reporting to the state of all infections resulting from treatment with strong fines for non-compliance. It would require state approval before closing clinics or reducing services. And it would prohibit discrimination in treatment based upon your coverage; maintaining the same standards no matter what neighborhood youre in.

The clinic private industry spent over 100 million dollars to defeat Proposition 8 and it looks to be spending a similar amount against Proposition 23. Proposition went down in flames, partly because the American Nurses Association opposed it, though the more progressive California Nurses Association was curiously silent in 2018 and is not taking a position this time.

I do have some reservations about a ballot measure like this one. The initiative process is probably not the best vehicle to set medical treatment policy. I mean, do dialysis patients really need a medical doctor present, or are skilled nurses more than adequate? I dont know the answer to that question, and maybe thats the reason the CNA is staying out of this fight. This is the type of question which should be addressed by taking input in legislative committee with experts making their pitches one way and the other. But I have absolutely no doubt that in the affluent area clinics there is at least one physician present always, if only to give the affluent peace of mind.

And what I do know is that a for-profit model of health care is problematic when it is allowed to close clinics in poor areas and cut corners in treatment for patients whose coverage pays less after having displaced public and/or non-profit clinics. We hear the private insurers and health industry touting the benefits of free enterprise in generating the best care for everyone, but when expected to make good on those promises they say, Hey, were trying to run a business here! And in fact, they are cynically arguing that the SEIU wants to drive costs of operation up so that private businesses will close because unionization of dialysis workers has been difficult, which is patently ridiculous on several different levels.

And if having to report infections is really a cost-prohibitive burden, then maybe youre infecting too many people!

Note to the industry show us that your vaunted for-profit business model works and support these very basic regulations. That you are spending tens of millions to oppose this is really telling.

Proposition 24 Convoluted Consumer Privacy Protection Measure No

In 2018 the Legislature passed the California Consumer Protection Act, which is said to provide the strongest protection of digital consumer privacy of any state in the country, requiring permission from consumers before certain private information could be shared. Almost immediately tech companies and other businesses pushed to weaken it. And in fact, several bills to overhaul the law were stopped by State Senator Hannah-Beth Jackson who used her power as chair of the Judicial Committee to block them. She will be termed out next year, and the feeling of consumer privacy activists is that if the protections are not locked in by a ballot proposition which can only be amended by a subsequent ballot proposition the reforms will be lost or significantly watered down. The man who is spending a great deal of money to pass the measure is Alistair McCallister who says, There is basically unlimited resources on one side of the fight. If you dont do anything, they will win eventually.

Andrew Yang is also supporting it.

Im not even going to try to list the provisions of the 2018 law. Its huge. Here is the text if you want to read or skim it: https://theccpa.org/

What Proposition 24 adds is the creation of an enforcement agency; the removal of the opportunity to correct a violation to avoid penalty; to honor all consumer requests against the sharing of the designated information; allowing consumers an opt out for use of their sensitive personal information for advertising or marketing purposes; requiring affirmative permission for the use of information for anyone younger than 16; requiring parental permission for anyone under 13; and requiring that a business correct false consumer information upon request.

The measure attempts to eliminate some loopholes which have undermined the CCPA. For one thing, as noted earlier, it requires permission for a consumers information to be sold. But most of the data isnt sold at all. Websites willingly give their data to platforms like Facebook or Google in order to make it easier for them to sell their own subscriptions and advertising. The law also exempted companies designated service providers using the data for microtargeting advertising. Well, thats pretty much most of what Facebook and Google does for its advertising clients. Apparently Proposition 24 attempts to shut that down.

It all sounds good. So why are the ACLU, Dolores Huerta, the California Nurses Association, the Council on Islamic American Relations, the Media Alliance, and half a dozen consumer organizations opposed to it? The Devil is in the 52 pages of details. From the San Francisco Chronicle: Overall, its a step backward, said Jake Snow, an attorney for the American Civil Liberties Union of Northern California. It doesnt take into the account the burdens on poor communities and communities of color to pay for their privacy and to do the work to protect themselves.

Opponents say that the law would create a loophole which would allow the sale of small businesses many of whom do not have the time and money to go to the intricate lengths needed to attain the privacy and would aggravate what is being referred to as digital redlining or the digital divide in which poor people, disproportionately of color, are left behind. Proposition 24 allows companies to institute pay for privacy by charging more to those who opt out of sharing their information. CCPA already allows it to some degree, but this measure would entrench it, again, requiring a further ballot measure to change. If you are lower income you are going to opt for the lower rate and therefor it only benefits those for whom the difference in rates is no serious concern.

But the biggest issue is that the 52 pages of legalese is so dense that legal experts are disagreeing on the impact. I cant make sense out of much of it and Im an attorney. One example is over whether companies can by-pass the CCPA requirement of an opt-out app which basically notifies any business of the opt-out choice rather than having to manually opt out of each site, one by one. And were talking about 300 data brokers based in California. Proposition 24 seems to provide an out for the requirement to honor your app-conveyed wishes by offering an opt-out button somewhere on the website. But legal advocates for the measure argue that a few paragraphs later it says that businesses must honor global opt-outs and that the choice the businesses have are an opt-out button and forgoing the ability to charge more to opt-out customers. I cant be certain. It would have to be fought out in court, and unfortunately, a ballot proposition does not have any legislative history to guide interpretation.

Meanwhile, the California Democratic Party is neutral on the measure as is the Electronic Frontier Foundation which described the measure as a mixed bag of partial steps backwards and forwards.

And there are advocates who acknowledge the measures shortcomings, but fear that the gains of 2018 could be lost before a better measure is submitted and passed. Apparently, the pressure on the legislators is intense.

Another example the whole point is that Proposition 24 is supposed to prevent future legislation from weakening CCPA while allowing legislation to strengthen it. The measure specifies that any legislative amendments must be consistent with and further the purpose and intent of this Act, in order to further protect consumers rights, including the constitutional right of privacy. But then the measure lists 23 specific principles to be considered in the implementation of the policy as well as subsequent legislation including, for example avoiding anything which will stifle the development of new technology or place the consumer in a position to knowingly and freely negotiate with a business over the business use of the consumers personal information. This raises the fear that the initiative could, perversely, block the legislature from expanding privacy protections. What if there is legislation which places additional restrictions which will allow a company argue in court that this deprives users of the right to negotiate?

I could list further objections and ambiguities, but the problem is that for all its good intentions this is too complicated a measure to be decided by ballot. I sure hope we dont lose existing privacy protections, but if we do then maybe we can revisit them in a future ballot proposition. Democracy often does give the economically powerful an advantage in the process, but that is not an excuse to bypass democracy. And if lawyers cant even agree on the actual effect of the law, what chance does everyone else have to sort it out?

Sorry, no. I hate to vote against something like this because the media and political consensus might conclude that people really dont care about consumer privacy rights. But there is simply no way I can vote for a measure which gives me, an attorney, a splitting headache.

Proposition 25 Confirms Electorate Support of Bail Ban Yes

Careful with this measure. It was placed onto the ballot by people who oppose the legislatures 2018 ban of the bail system under a specific provision of the law which requires voter confirmation of certain types of laws passed before such law takes effect. Therefor a yes vote is to uphold the bail ban law and a no vote essentially repeals it.

See more here:
How to Vote This November: A Progressive's Opinion Redheaded Blackbelt - Redheaded Blackbelt

Cell Harvesting Market to Witness Steady Expansion During 2018-2023 – The Market Records

The global market for cell harvesting should grow from $885 million in 2018 to reach $1.5 billion by 2023 at a compound annual growth rate (CAGR) of 11.3% for the period of 2018-2023.

Report Scope:

The scope of the report encompasses the major types of cell harvesting that have been used and the cell harvesting technologies that are being developed by industry, government agencies and nonprofits. It analyzes current market status, examines drivers on future markets and presents forecasts of growth over the next five years.

The report provides a summary of the market, including a market snapshot and profiles of key players in the cell harvesting market. It provides an exhaustive segmentation analysis of the market with in-depth information about each segment. The overview section of the report provides a description of market trends and market dynamics, including drivers, restraints and opportunities. it provides information about market developments and future trends that can be useful for organizations, including wholesalers and exporters. It provides market positionings of key players using yardsticks of revenue, product portfolio, and recent activities. It further includes strategies adopted by emerging market players with strategic recommendations for new market entrants. Readers will also find historical and current market sizes and a discussion of the markets future potential. The report will help market players and new entrants make informed decisions about the production and exports of goods and services.

Get Access to sample pages @ https://www.trendsmarketresearch.com/report/sample/11685

Report Includes:

41 data tables and 22 additional tables Description of segments and dynamics of the cell harvesting market Analyses of global market trends with data from 2017, 2018, and projections of compound annual growth rates (CAGRs) through 2023 Characterization and quantification of market potential for cell harvesting by type of harvesting, procedure, end user, component/equipment and region A brief study and intact information about the market development, and future trends that can be useful for the organizations involved in Elaboration on the influence of government regulations, current technology, and the economic factors that will shape the future marketplace Key patents analysis and new product developments in cell harvesting market Detailed profiles of major companies of the industry, including Becton, Dickinson and Co., Corning, Inc., Fluidigm Corp., General Electric Co., Perkinelmer, Inc., and Thermo Fisher Scientific, Inc.

Summary

Stem cells are unspecialized cells that have the ability to divide indefinitely and produce specialized cells. The appropriate physiological and experimental conditions provided to the unspecialized cells give rise to certain specialized cells, including nerve cells, heart muscle cells and blood cells. Stem cells can divide and renew themselves over long periods of time. These cells are extensively found in multicellular organisms, wherein mammals, there are two types of stem cells embryonic stem cells and adult stemcells. Embryonic stem cells are derived from a human embryo four or five days old that is in the blastocyst phase of development. Adult stem cells grow after the development of the embryo and are found in tissues such as bone marrow, brain, blood vessels, blood, skin, skeletal muscles and liver. Stemcell culture is the process of harvesting the exosomes and molecules released by the stem cells for the development of therapeutics for chronic diseases such as cancer and diabetes. The process is widely used in biomedical applications such as therapy, diagnosis and biological drug production. The global cell harvesting market is likely to witness a growth rate of REDACTED during the forecast period of 2018-2023.The value of global cell harvesting market was REDACTED in 2017 and is projected to reach REDACTED by 2023. Market growth is attributed to factors such as increasing R&D spending in cell-based research,the introduction of 3D cell culture technology, increasing government funding, and the growing prevalence of chronic diseases such as cancer and diabetes.

The growing incidence and prevalence of cancer is seen as one of the major factors contributing to the growth of the global cell harvesting market. According to the World Health Organization (WHO), cancer is the second-leading cause of mortality globally and was responsible for an estimated 9.6 million deaths in 2018. Therefore, there is an increasing need for effective cancer treatment solutions globally. Cell harvesting is the preferred method used in cancer cell-related studies including cancer cell databases (cancer cell lines), and other analyses and drug discovery in a microenvironment. The rising prevalence of such chronic diseases has led governments to provide R&D funding to research institutes and biotechnology companies to develop advanced therapeutics. Various 3D cell culture technologies have been developed by researchers and biotechnology companies such as Lonza Group and Thermo Fischer Scientific for research applications such as cancer drug discovery. The application of cell culture in cancer research is leading to more predictive models for research, drug discovery and regenerative medicine applications.

Platelet-rich plasma (PRP) therapy, a new biotechnology solution that has a heightened interest among researchers in tissue engineering and cell-based therapies, has various applications in the treatment of tissue healing in tendinopathy, osteoarthritis and muscle injury. It has been conventionally employed in orthopedics, maxillofacial surgery, periodontal therapy and sports medicines. PRP therapy can be used in the treatment of fat grafting, acne scars, and hair regrowth.

Major factors driving market growth include increasing healthcare costs and the high rate of adoption for modern medicines in emerging economies such as China and India. It has been estimated that India will witness a CAGR of REDACTED in the cell harvesting market during the forecast period. The active participation of foreign pharmaceutical companies has tapped the Indian healthcare sector with a series of partnerships and mergers and acquisitions, which in turn is positively impacting the growth of the market in this region. Consistent development and clinical trials for stem cell therapies, plus contribution from the government and private sectors through investments and cohesive reimbursement policies in the development of cancer biomarkers, is further fueling market growth. InSweden, a research team at Lund University has developed a device to collect fluid and harvest stem mesenchymal stem cells (MSCs). The device is developed with 3D-printed bio-inert plastics which, when used by doctors, can result in the safe extraction of fluids (medical waste) from the patients body. The liquid is then passed through a gauze filter for purifying thoroughly and MSCs are separated from the fluid by centrifugation and are grown in culture.

More:
Cell Harvesting Market to Witness Steady Expansion During 2018-2023 - The Market Records

No on Prop 14: Not the best way to support stem-cell research – Los Angeles Times

In 2004, after President George W. Bush cut off all federal funding for embryonic stem-cell research on religious grounds, Californians strongly backed Proposition 71, a $3-billion bond measure to fund this kind of research, even though such funding is usually not the purview of states.

Supporters of the proposition including this editorial board believed it would allow California to stand out as a leader in this field, advance a budding avenue of research that might save lives and alleviate suffering, bolster its biotech sector and fund possible blockbuster treatments that might earn the state royalties as well. Embryonic stem cells are particularly valuable to research because they are undifferentiated, meaning they do not have a particular function, and researchers could conceivably turn them into specialized cells in order to regenerate human cells and tissue.

In the years since, Proposition 71 gave rise to a burst of scientific discovery. Two cancer treatments it helped fund, for blood and bone-marrow cancers, have been approved by the FDA, though neither of those employed embryonic stem cells and could have been funded even under Bush administration rules. It has also supported promising advances in the treatment of diabetes, bubble boy immune deficiency and vision-robbing retinitis pigmentosa, but other efforts have fallen short in clinical trials.

Moreover, the money helped build laboratories and other infrastructure that give California a head start on research and development, making the state the it place for stem-cell research. Researchers in the state moved to the head of the pack for private grants, because projects are less likely to need the time and money to create facilities before work can begin.

Now that Proposition 71 funding has practically run out, the issue is back on the November ballot with Proposition 14, which seeks nearly double the amount worth of bonds $5.5 billion to continue the juggernaut.

This time, voters should reject the measure, with the caveat that the issue could be reconsidered in a couple of years, if its proponents bring it back in better-designed and more modest form and if there are more successes in human trials and financial payback.

We have long had reservations about how the California Institute for Regenerative Medicine, established as a result of Proposition 71, was set up. Though funded publicly, it is not overseen by the governor and Legislature like other state agencies, and its governing board is too large, at 29 members. Those members generally have ties to the advocacy organizations and research institutions that have received most of the money.

The driving force behind the initiative has been Robert N. Klein II, a Bay Area lawyer and real estate investor. There is no doubting Kleins sincerity in his cause. He knows too well the suffering inflicted by intractable diseases; his son Jordan died of complications of Type I diabetes in 2016. His accomplishment in persuading the state to invest billions in a specific avenue of biomedical research has been exceptional.

However, Klein developed these initiatives largely behind closed doors with little to no public input; he has strong ideas about how things should be run on the stem-cell front and has steadfastly resisted more government oversight. Thats fine when hes investing his own money; its a fatal flaw when he is asking voters for nearly $8 billion, the estimated cost of paying off the bonds over time, according to the Legislative Analysts Office.

Kleins role and the bloated structure of CIRMs super-sized governing board have given rise to some serious ethical mishaps, including a board member who improperly intervened to try to get funding for his organization. (He is no longer on the board.) After this and several other examples of impropriety, rules were tightened. Board members must recuse themselves from votes when there is a conflict of interest, but with 29 members who all want certain projects to receive funding, there is too much potential for mutual back-scratching. Instead of repairing this problem, the new proposition would expand CIRMs board to 35 members and retain its troubling independence from oversight by the governor and Legislature, leaving it open to further conflicts of interest.

Proposition 71 hasnt yet yielded a significant financial return on investment for the state or the cures that were ballyhooed at the time. Though no one ever promised quick medical miracles, campaign ads strongly implied they were around the corner if only the funding came through. Proponents oversold the initiatives and voters cant be blamed if they view this new proposal with skepticism.

In the years since Proposition 71 passed, more resources have become available. President Obama reversed Bushs order and restored federal funding, which meant that between CIRM and the National Institutes of Health, along with private grant and investment funding, stem-cell research has been healthy, if not downright flush. That funding has stayed and even grown under President Trump, to more than $2 billion a year, with about $321 million of that in human embryonic stem-cell research. (There have, though, been recent threats to embryonic research from a group of conservative senators.)

The idea was never for California to become the long-term replacement for federal funding. It was to kick-start an industry that would then operate on its own. If that has failed to happen under Proposition 71 as promised, it shouldnt be the responsibility of California taxpayers to fix it. Thats especially true right now, at a time of yawning needs to address the cost of twin health and economic crises and the worsening effects of climate change. Private money for stem cell-work will continue to be available; its not as though research will collapse.

No doubt, the pace of responsible science is incremental and the outcomes uncertain even with the best research efforts. Yet the backers still couch the possibilities in grandiose terms. In a recent interview with the Times editorial board, Klein talked about the money that would be saved by wiping out Alzheimers disease which has so far has frustrated attempts to treat it effectively, despite many billions of dollars in research.

Embryonic stem cell research remains important, and there might be ways in which the state can contribute less grandiose funding while maximizing its investment. For example, scientific research has a well-known valley of death, where many projects cant get funding to make the transition from laboratory to human clinical trials.

Offering some matching help to get projects through that phase might attract businesses and scientists to California, while spending far less than the billions proposed in Proposition 14. Its worth noting that stem-cell work isnt the only kind of research that faces the valley of death problem; its an issue for most basic research that seeks to make the leap to human trials and that might be equally in need of state help.

Now is not the time for a huge new investment in specialized medical research. First, it makes sense to wait until after the election; if Democrats do well, there should be growing support for embryonic stem-cell research at the federal level, which is where such funding should take place. The future of Californias pandemic-battered economy and budget remains to be seen. Waiting also would give voters a chance to find out how well the states stem-cell research projects continue without state dollars, and whether some of the promising advances lead to breakthrough therapies and a return on Californias investment.

There would be an opportunity to rethink and rewrite any future proposals, which should include a far more modest ask of taxpayers as well as fixes to the structure and inflated size of the CIRM board. The institute should also be placed under the same state oversight as other agencies reporting to the governor.

If CIRM needs money for a basic operating budget over the next couple of years, that could be covered by the states general fund. The agency still needs to administer already-funded projects and could use that time to discuss a more affordable path forward. Right now, the state has other, more urgent spending priorities.

Editors note: This newspapers owner, the physician and scientist Dr. Patrick Soon-Shiong, played no role in the editorial boards deliberations on this measure.

Go here to read the rest:
No on Prop 14: Not the best way to support stem-cell research - Los Angeles Times

Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations – BioSpace

GOLDEN, CO / ACCESSWIRE / October 1, 2020 / Vitro Diagnostics, Inc. (OTCQB:VODG), dba Vitro Biopharma, announced its 3rd quarter, ended July 31st 2020, financial results of operations.

Vitro Biopharma recorded 3rd quarter revenues of $132,066 vs $225,191 a decrease of 41% over the comparative quarter last year. Revenues were up slightly from the prior quarter which were $128,631. The decrease in revenue is directly attributed to the COVID 19 pandemic. Lockdown extensions and business opening limitations have pushed our expectations of growth and revenue recovery out to the first half of 2021. Feedback from our customers and our partner clinic in the Cayman Islands http://www.DVCstem.com are that patients awaiting treatments are not dropping off, but merely postponing their treatments and as such, a significant backlog is building. The cosmetic clinics http://www.Infinivive.com have started to open up but only with lower occupancy and variations by state, resulting in reduced revenue into the 4th quarter with expectations of a revival of revenue into the first half of 2021.

Gross profit declined 3% from the comparative quarter last year primarily due to the reduced higher margin stem cell product sales versus the mid margin stem cell research and development products.

Overall operating expenses increased in the quarter ended July 31st 2020 by $180,326 to $336,442 from $194,682 in the prior year's comparative quarter. The increase in expenses reflects the increased costs of FDA regulatory, legal, consulting, and audit costs. We engaged the audit firm of MaloneBailey LLP to get the company fully reporting around January of 2021.

Vitro Biopharma Announces MaloneBailey L.L.P. as its new Auditors

The company added extra resources to turn its attention to the world-wide challenge of finding therapies to fight COVID-19. Vitro filed an Investigational New Drug ("IND") application and through its collaboration with GIOSTAR, received FDA authorization to treat COVID 19 patients under the Expanded Access Program with its AlloRx Stem Cells . A single patient was treated successfully with no adverse events and the patient showed evidence of improved lung, liver and kidney function while also recovering from a stroke-induced coma.

Critically ill COVID-19 Patient Successfully Treated with Vitro Biopharma’s AlloRx Stem Cells®

The company entered into an MOU with GIOSTAR, a leading global stem cell research company, who operates multiple international stem cell clinics. The supply agreement provides GIOSTAR with the use of our AlloRx Stem Cells to treat COVID 19 patients through FDA-pre and post-market approval.

Vitro Biopharma Signs MOU with GIOSTAR for COVID-19 IND Using AlloRx Stem Cells

During and subsequent to the quarter the company achieved and pursed the following objectives:

During the quarter and subsequent to the quarter, the company continued with its Series A Convertible Preferred Stock offering to accredited investors under the SEC Regulation D exemption. The preferred Stock is priced at $25 per share which is convertible at $0.25 cents per share for a total of 100 shares. The minimum investment is $50,000 per unit. The company has sold $1.0 million of the Series A Convertible Preferred Stock during and subsequent to the quarter. The offering was sold out at $1.0 million and the company has expanded it to a total of up to $3.5 million to ensure sufficient working capital during the Coronavirus pandemic and to start the regulatory process of current reporting audits and funding for its expanded clinical trial activities with the FDA.

As a part of our overall strategy to target both global and US stem cell markets, Vitro submitted a Phase I IND application to the FDA to assess the safety of AlloRx Stem Cells in the treatment of COVID-19. We have established strong communication channels with FDA officials to facilitate our IND review and are providing additional information to the FDA to complete the approval of our IND. Several clinical centers have expressed interest in our stem cell therapy and we continue to enlist multi-center sites to conduct our Phase 1 trial. We are also pursuing other avenues for emergency use under the Expanded Access Program. No adverse events were reported and the patient who had various comorbidities stabilized and exhibited enhanced pulmonary, liver and renal function during the six weeks following AlloRx Stem Cell Therapy. The patient has now recovered and is at home from the hospital after 3 months of intensive care. We are currently pursuing additional emergency use authorizations under expanded access provision applications through our collaboration with GIOSTAR. MSCs have been shown to block the cytokine storm that occurs in COVID-19 patients in acute respiratory distress through their powerful anti-inflammatory effects. The cytokine storm leads to the need for assisted breathing by ventilators, transfer to ICU and related burdens on the US health care system. It is important to note that AlloRx Stem Cells are a possible therapy for other viral attacks including influenza. Stem cells may block acute respiratory distress and may repair damage to other major organs including cardiovascular, pulmonary, hepatic and renal systems. AlloRx Stem Cells have been shown to assist in recovery from failure of various organ systems in COVID-19 survivors, as our case study and results from several other labs are demonstrating.

The Company entered into an exclusive Memorandum of Understanding (MOU) with Global Institute of Stem Cell Therapy and Research, Inc. ("GIOSTAR") a leading stem cell research institute based in San Diego, California. GIOSTAR has filed for a separate IND application using Vitro Biopharma's umbilical cord mesenchymal stem cell product AlloRx Stem Cells in a clinical trial to treat COVID-19 patients. GIOSTAR has already obtained emergency use authorization under expanded access provisions from the FDA for severe COVID-19 hospitalized patients using AlloRx Stem Cells.

Vitro continues to seek FDA authorization of its pending IND. As the approval process proceeds, Vitro will seek AlloRx Stem Cells FDA approval through Phase 2/3 IND filings for other indications such as osteoarthritis while at the same time continuing to supply GIOSTAR AlloRx Stem Cells for treatment of COVID-19 patients in global markets.

The company has delayed the expansion of its laboratory and manufacturing facilities to better reflect the delays in revenue brought on by the pandemic. This new facility is expected to be operating in the second half of 2021. Our present facility has approximately $6M of AlloRx Stem Cell Vitro Biopharma revenue capacity per year. Furthermore, the completion of the 2nd clean room processing facility would expand our potential capacity to approximately 100 Billion AlloRx Stem Cell s a month or approximately $1.7 Million of AlloRx Stem Cell revenue capacity per month. This would give Vitro Biopharma a revenue run rate capacity of $20M a year.

Our increased capacity is rigorously controlled by our Quality Management System, now certified to the ISO9001 Quality Standard and the ISO13485 Medical Device Standard as well. This provides cGMP-compliant manufacturing of the highest quality stem cells/medical devices for clinical trial testing to provide further evidence of safety and efficacy for treatment of a wide variety of indications. Highly regulated cGMP biologics manufacturing within a BLA-compliant facility provides numerous opportunities to the Company to drive strong revenue growth. We are presently focused on our partnerships in the Caribbean with DVC Stem in Grand Cayman Island, InfiniVive MD in the US and emerging opportunities in the The Medical Pavilion of the Bahamas We are actively pursuing other partnership opportunities as well.

We have reformulated with our contract manufacturer to produce STEMulize in large quantity manufacturing runs. STEMulize contains natural substances that activate the body's own stem cells to enhance recovery from injury such as TBI, stroke, MS, PD and other autoimmune, inflammatory and neurological diseases. The STEMulize product will be offered as a private label product to Infinivive MD clinics and is being implemented as supplemental support to clinical treatments now ongoing in the Cayman Islands. Patients report positive benefits fromSTEMulize therapy following stem cell transplants including increased overall energy and enhancement of improved motor function in MS patients. We are currently pursing licensing arrangements with nutraceutical companies that can scale our formulation under their own private label.

The Company's cosmetic stem cell serum private labelled as Infinivive MD is being applied as a topical cosmetic serum in medical spas and plastic surgery offices. Infinivive MD revenue was reduced by the Coronavirus pandemic and as a result, revenues declined by 52% in the current quarter to approximately $50,000 vs $105,000 in the prior comparative quarter in 2019. This revenue has been flat from the prior quarter reflecting the reduced treatments due to the pandemic capacity limitations of various states.

Infinivive MD Cosmetic Serum is revolutionizing the cosmetic industry. Patients are experiencing unparalleled improvements in the appearance of fine lines and wrinkles. This is one of the fastest growing revenue streams for Vitro Biopharma.. We work with a variety of regulatory experts to assist us in the appropriate regulatory pathways.

http://www.jackzamoramd.com http://www.infinivivemd.com

Vitro Biopharma's OEM cosmetic topical serum is being distributed exclusively by Infinivive MD into cosmetic clinics that are providing the topical treatment as a beautification product. To date the company's product is being offered in a number of clinics throughout the United States and soon internationally,; but with the clinics just opening again for business and with limited occupancy rules we do not expect this revenue to recover back to peak levels with growth until the first half of 2021.

The company has brought on Dr. Jack Zamora as its chief medical officer (C.M.O.) and together we have developed a new exosome product, Infinivive MD's Cosmetic Exosome Serum.

Vitro Biopharma Announces Jack Zamora M.D. as it’s Chief Medical Advisor

The product will be distributed by InfiniveMD along with the topical stem cell serum. The product is also used as a topical application for beautification. The product is a compliment to the topical stem cell serum and will provide the customer with a more competitive price point per application depending on the particular clinic. The new Exosome product

is being marketed and sold into the clinics in the first half of 2021. We are jointly working

on a topical Daily Serum. The Exosome market is part of the billion-dollar cosmetic market in the United States. These products will also be sold offshore around the world.

Update on the Clinical Trial of Musculoskeletal Conditions in the Bahamas

This initiative broadens Vitro Biopharma's expansion into highly regulated stem cell trials in collaboration with the Nassau-based Medical Pavilion of the Bahamas (TMPB).

Home

We will now be able to extend stem cell therapy based on our novel, patent-pending AlloRx Stem Cell product to a variety of musculoskeletal conditions. These include OA of any joint, ACL/MCL tear, Achilles tendon rupture, rotator cuff injury, tennis elbow and herniated disc that are highly prevalent and have few disease-modifying options. It is important to note that many stem cell treatments now performed are problematic due to limited potency and failure to meet basic criteria of stem cells. Vitro Biopharma operates a highly regulated, FDA-compliant commercial biologics manufacturing operation for several years and is cGMP compliant, ISO 9001Certified, ISO 13485 Certified, CLIA Certified and FDA registered and BLA-compliant. All manufacturing occurs in a certified sterile clean room with extensive and advanced testing to assure the absence of contamination. Furthermore, in numerous patients treated to date by IV infusion of AlloRx Stem Cells there have been no significant adverse events. The company is partnered with Dr. Conville Brown, MD, MBBS, FACC, FESC, PhD, the founder and CEO of the Medical Pavilion of the Bahamas who is the Principal Investigator of this trial and director of its clinical administration. Dr Brown was instrumental in the establishment of the NSCEC in the Bahamas.

About the Medical Pavilion of the Bahamas: TMPB operates within a 40,000 square foot building as a partnered care specialty medical facility with 10 different centers in various areas including cardiology, cancer, clinical research and kidney disease. One of the centers is the Partners Stem Cell Centre, where the present trial will be conducted. The Partners Stem Cell Centre provides an environment to conduct stem cell research and clinical trials under the model of ''FDA rigor in a Non-FDA Jurisdiction'' TMPB employs 20 medical specialists in various fields. See http://www.tmp-bahamas.com for additional information.

The company has entered into an operating agreement with the Partner's Stem Cell Centre and expects to begin patient enrollment for the clinical trial in QI/QII of 2021 once

the Bahamas opens up without quarantine restrictions.

Due to the Corona virus pandemic the Cayman Islands closed itself and its businesses down for the majority of the quarter and next quarter, the current status is listed as locked down until Oct. 1st 2020. However, our partner reports that customers are staying on the waiting list and will return for their treatments as soon as the island opens back up. There currently is a pending backlog of over 70 patients seeking treatment which exceeds all of the treatments performed in 2019 by over 200%. We expect to see a surge in revenues from this backlog to bring back our revenue stream in the into the first half of 2021.

The Company has 11 patent applications pending in the US and foreign jurisdictions. These patents cover our AlloRx Stem Cell line and various aspects of our STEMulize stem cell activation products and processes as well as specific diagnostic tests of stem cell activity and therapeutic effectiveness. During the quarter, the Company has responded to office actions and continues to vigorously prosecute & expand its patent filings.

Dr. Jim Musick, CEO of Vitro Biopharma, said, "We are pleased to report our activities in fighting the COVID-19 with filings of our eIND, INDs and partnership with GIOSTAR. While we are disappointed in the extraordinary events of the Corona Virus pandemic and its results on our operations, we have taken the time to advance our clinical applications, partnerships and new product development in further preparation for realized growth in 2021 as a result of these activities. In addition, with have started the intense process of organizing the company for audits and fully reporting status with the SEC targeted for January 2021.

We believe our stem cell products are distinctly superior to stem cell treatments offered in the USA. The latter usually involve use of impure products lacking validation as stem cells and containing insufficient numbers of stem cells to achieve therapeutic benefits. These are produced without regulatory oversight and have been known to cause serious adverse effects. Hence the use of highly purified and well characterized stem cells (AlloRx Stem Cells) is needed to provide safety and efficacy in regenerative medicine therapies.

In summary, Vitro Biopharma is advancing as a key player in regenerative medicine with 10+ years' experience in the development and commercialization of stem cell products for research, recognized by a Best in Practice Technology Innovation Leadership award for Stem Cell Tools and Technology and a growing track record of successful translation to therapy. We plan to leverage our proprietary technology platform to the establishment of international Stem Cell Centers of Excellence and regulatory approvals in the US and worldwide.

Vitro Biopharma has supplied major biopharmaceutical firms, elite university laboratories and clinical trials worldwide with its Umbilical Cord Mesenchymal Stem Cells (AlloRx Stem Cells), and it's MSC-Grow Brand of cell culture media along with advanced stem cell diagnostic services. http://www.vitrobiopharma.com"

Sincerely yours,

James R. Musick, PhD.

President, CEO & Chairman of the Board

http://www.vitrobiopharma.com

Forward-Looking Statements

Statements herein regarding financial performance have not yet been reported to the SEC nor reviewed by the Company's auditors. Certain statements contained herein and subsequent statements made by and on behalf of the Company, whether oral or written may contain "forward-looking statements". Such forward looking statements are identified by words such as "intends,"

"anticipates," "believes," "expects" and "hopes" and include, without limitation, statements regarding the Company's plan of business operations, product research and development activities, potential contractual arrangements, receipt of working capital, anticipated revenues and related expenditures.

Factors that could cause actual results to differ materially include, among others, acceptability of the Company's products in the market place, general economic conditions, receipt of additional working capital, the overall state of the biotechnology industry and other factors set forth in the Company's filings with the Securities and Exchange Commission. Most of these factors are outside the control of the Company. Investors are cautioned not to put undue reliance on forward-looking statements.

Except as otherwise required by applicable securities statutes or regulations, the Company disclaims any intent or obligation to update publicly these forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT:

Dr. James Musick 4621 Technology Drive Golden, CO 80403 (303) 999-2130 x1 http://www.vitrobiopharma.com

Vitro Diagnostics, Inc.

Quarter Ended July 31st;

Income Statement

Stem Cell Therapies and Treatments

Stem Cell Products

Other Services

Total Revenues

COGS

Gross Profit

SGA Expenses

Office Expenses

Consulting,Accounting,Legal and Banking Fees

Laboratory R&D & Quality Control

Total Operating Expenses

Net Operating Profit (Loss) EBITDA

Non Cash Depreciation and Amortization

Non Cash Stock for Services

Non Cash Interest on Shareholder Debt

Non Cash Interest on Secured Notes Payable

Net Income (Loss)

The company provides its financial information for investor purposes only, the results published are not audited or necessarily SEC or GAAP compliant.

Vitro Diagnositics Inc.

Quarter Ended July 31st;

Balance Sheet

ASSETS

Cash

Accounts Receivable

Inventory

Notes Receivable and Prepaids

Current Assets

Fixed Assets

Intangible and other Assets

Total Assets

LIABILITIES

Trade Accounts Payable

Bank Credit Cards

Capital Lease Obligaitons

Current Liabiities

Secured Convertible Notes with discount

Capital Lease Obligations

Shareholder Accrued Comp. Payable

Shareholder Debts Payable

Long Term Liabilities

Total Liabilities

SHAREHOLDERS EQUITY

Series A Convertible Preferred

Common Stock

Paid in Capital

Treasury Stock

Retained Earnings

See original here:
Vitro Biopharma 3rd Quarter ended July 31st 2020 Financial Results of Operations - BioSpace

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials – PR Web

Asymmetrex discusses new advances for supply of traditional drug development and advanced therapy medicinal product (ATMP) clinical trials

BOSTON (PRWEB) October 01, 2020

Adapting to the present COVID crisis, this year the 2020 Outsourcing in Clinical Trials USA Conference, one of several international clinical trials supply trade conferences organized by Arena International Events Group each year, adopted a virtual meeting format. The conference, scheduled for September 30-October 1, continued its tradition of bringing together contract research organization suppliers and company sponsors in the clinical trials supply industry to discuss new developments and best practices.

Among the many industry members invited to speak in the event, James L. Sherley, M.D., Ph.D., founder and director of Massachusetts stem cell biotechnology company Asymmetrex, presented on September 30. Dr. Sherleys presentation highlighted a growing new area of the clinical trials supply industry. More and more, the clinical trials supply industry is considering better technology and practices to support stem cell clinical trials and gene therapy clinical trials that utilize advanced therapy medicinal products. In particular, Dr. Sherley discussed the value of implementing new quantification technologies for ATMPs developed with tissue stem cells. He answered the rhetorical question that was the title of his talk How can we outsource stem cell clinical trials without counting tissue stem cells? by detailing places in ATMP supply chains where instituting counting technologies would provide significant benefits to the stem-gene clinical trials supply industry and the patients it serves.

Sherley also presented innovation proposals for traditional pharmaceutical and biopharmaceutical clinical trials supply. He described how tissue stem cell counting technologies represented advantages both for discovery of novel drugs and for toxicology evaluations of new drug candidates. A major value presented was the opportunity for drug companies to realize hundreds of millions of dollars in reduced costs each year by using tissue stem cell counting tests for earlier identification of drugs that would fail late in clinical trials because of inducing chronic failure of organs and tissues like the liver and bone marrow. Currently applied animal toxicology studies miss many drugs with this disastrous character. Sherley described how such drugs could be detected in inexpensive cell culture tests by counting how stem cell-specific number and viability changed in their presence.

Though not a main focus of the presentation, Sherley ended his presentation with acknowledgement of Asymmetrexs recent introduction of the first-in-kind technology for counting therapeutic tissue stem cells and determining their dosage. The company holds issued patents for the technology and its use for drug evaluations in both the U.S. and U.K. In August of this year, it published a peer-reviewed report, co-authored with its partner AlphaSTAR Corporation, that describes the new method and its applications for stem cell therapy and drug evaluations. In September, the company was awarded a research and development grant from the National Institutes of Health-National Heart, Lung, and Blood Institute for continued development of the technology and its commercialization. These plans for the companys AlphaSTEM Test tissue stem cell counting technology were recently reported.

About Asymmetrex

Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. The companys U.S. and U.K. patent portfolio contains biotechnologies that solve the two main technical problems production and quantification that have stood in the way of effective use of human adult tissue stem cells for regenerative medicine and drug development. Asymmetrex markets the first technology for determination of the dose and quality of tissue stem cell preparations (the AlphaSTEM Test) for use in stem cell transplantation therapies and pre-clinical drug evaluations. Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA and the Massachusetts Biotechnology Council.

Share article on social media or email:

See original here:
Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials - PR Web

Stem cells can repair Parkinson’s-damaged circuits in mouse brains – University of Wisconsin-Madison

The mature brain is infamously bad at repairing itself following damage like that caused by trauma or strokes, or from degenerative diseases like Parkinsons. Stem cells, which are endlessly adaptable, have offered the promise of better neural repair. But the brains precisely tuned complexity has stymied the development of clinical treatments.

In a new study addressing these hurdles, University of WisconsinMadison researchers demonstrated a proof-of-concept stem cell treatment in a mouse model of Parkinsons disease. They found that neurons derived from stem cells can integrate well into the correct regions of the brain, connect with native neurons and restore motor functions.

The key is identity. By carefully tracking the fate of transplanted stem cells, the scientists found that the cells identity dopamine-producing cells in the case of Parkinsons defined the connections they made and how they functioned.

Coupled with an increasing array of methods to produce dozens of unique neurons from stem cells, the scientists say this work suggests neural stem cell therapy is a realistic goal. However, much more research is needed to translate findings from mice to people.

Su-Chun Zhang talks with a postdoctoral student in his research lab at the Waismam Center. Photo: Jeff Miller

The team, led by UWMadison neuroscientist Su-Chun Zhang, published its findings Sept. 22 in the journal Cell Stem Cell. The research was led by Zhang lab postdoctoral researchers Yuejun Chen, Man Xiong and Yezheng Tao, who now hold faculty positions in China and Singapore.

Our brain is wired in such an accurate way by very specialized nerve cells in particular locations so we can engage in all our complex behaviors. This all depends on circuits that are wired by specific cell types, says Zhang, a professor of neuroscience and neurology at UWMadisons Waisman Center. Neurological injuries usually affect specific brain regions or specific cell types, disrupting circuits. In order to treat those diseases, we have to restore these circuits.

To repair those circuits in the Parkinsons disease mouse model, the researchers began by coaxing human embryonic stem cells to differentiate into dopamine-producing neurons, the kind of cells that die in Parkinsons. They transplanted these new neurons into the midbrains of mice, the brain region most affected by Parkinsons degeneration.

Several months later, after the new neurons had time to integrate into the brain, the mice showed improved motor skills. Looking closely, Zhangs group was able to see that the transplanted neurons grew long distances to connect to motor-control regions of the brain. The nerve cells also established connections with regulatory regions of the brain that fed into the new neurons and prevented them from being overstimulated.

Both sets of connections feeding in and out of the transplanted neurons resembled the circuitry established by native neurons. This was only true for dopamine-producing cells. Similar experiments with cells producing the neurotransmitter glutamate, which is not involved in Parkinsons disease, did not repair motor circuits, revealing the importance of neuron identity in repairing damage.

To finally confirm that the transplanted neurons had repaired the Parkinsons-damaged circuits, the researchers inserted genetic on-and-off switches into the stem cells. These switches turn the cells activity up or down when they are exposed to specialized designer drugs in the diet or through an injection.

When the stem cells were shut down, the mices motor improvements vanished, suggesting the stem cells were essential for restoring Parkinsons-damaged brains. It also showed that this genetic switch technology could be used to fine-tune the activity of transplanted cells to optimize treatment.

Zhang found that neurons derived from stem cells can connect with native neurons and restore motor functions. But more research is needed to translate the findings from mice to people.

The Zhang group and other researchers have spent years developing methods to turn stem cells into the many different types of neurons within the brain. Each neurological disease or injury would require its own specialized nerve cells to treat, but the treatment plans would likely be broadly similar. We used Parkinsons as a model, but the principle is the same for many different neurological disorders, says Zhang.

The work has personal meaning to Zhang. As a physician and scientist, he often receives letters from families desperate for help treating neurological disorders or brain trauma. Its also an experience he can relate to. Six years ago, Zhang was in a bike accident and broke his neck. When he awoke partially paralyzed in the hospital, his first thought was of how stem cells which he had already researched for years could help him recover.

Now, largely rehabilitated after years of physical therapy, Zhang still believes that the right stem cell treatments could, in the future, help people like him and the families he hears from.

To that end, Zhangs group is currently testing similar treatments in primates, a step toward human trials.

There is hope, but we need to take things one step at a time, he says.

This work was supported in part by the National Institutes of Health (grants NS096282, NS076352, and NS086604, MH099587 and MH100031).

Share via Facebook

Share via Twitter

Share via Linked In

Share via Email

See original here:
Stem cells can repair Parkinson's-damaged circuits in mouse brains - University of Wisconsin-Madison